Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007750 | 0.87 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18590305 | 0.81 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18598224 | 0.79 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL17078206 | 0.78 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4996013 | 0.78 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11861490 | 0.78 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL974467 | 0.78 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL14727725 | 0.77 | LMNA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL23779364 | 0.76 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11819410 | 0.75 | ALDH1A1 (0.46) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| WO-2021097427-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | CHRM1, RXFP3, NPY5R | GAA 2757/4885MGAM 4033/4885SI 4564/4885 |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | CHRM1, RXFP3, NPY5R | GAA 2757/4885MGAM 4033/4885SI 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.